# US 2022/0031770 A1 · Use of Megamonas funiformis in preventing and/or treating metabolic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031770 A1
- Document ID: US20220031770A1
- Status: Published application
- Kind: A1
- Application number: 17/296,423
- Filed: 2018-12-07
- Published: 2022-02-03
- Earliest claimed: 2018-12-07
- Assignees: Bgi Shenzhen
- Applicants: Bgi Shenzhen
- Inventors: Ying Dai; Yuanqiang Zou; Liang Xiao
- Web page: https://patentgrep.com/patent/US20220031770A1

## CPC

- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/205: Bacterial isolates
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided is a use of Megamonas funiformis in the prevention and/or treatment of metabolic diseases. Megamonas funiformis has the function of preventing and/or treating metabolic diseases (such as obesity, diabetes, atherosclerosis-related diseases, cardiovascular disease and hvperuricemia).

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A method for preventing and/or treating metabolic diseases, comprising:
administering a Megamonas funiformis or a composition comprising the Megamonas funiformis to a subject in need to prevent and/or treat the metabolic disease.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the Megamonas funiformis has a sequence of 16 s rDNA as shown in SEQ ID NO: 1 or with 99% or above sequence similarity to SEQ ID NO: 1.

### Claim 26 (depends on 24)

The method according to claim 24, wherein the Megamonas funiformis is Megamonas funiformis AF24-28AC with a deposit number of GDMCC 60093, Megamonas funiformis DSM 19343 or Megamonas funiformis JCM 14723, or a combination thereof.

### Claim 27 (depends on 24)

The method according to claim 24, wherein the Megamonas funiformis or the composition is administered orally.

### Claim 28 (depends on 24)

The method according to claim 24, wherein the subject comprises human or non-human mammal.

### Claim 29 (depends on 24)

The method according to claim 24, wherein the method is non-diagnostic or non-therapeutic.

### Claim 30 (depends on 24)

The method according to claim 24, wherein the metabolic disease comprises a lipid metabolism disease, a purine metabolism disease and/or an insulin metabolism disease;
preferably, the metabolic disease is selected from the group consisting of obesity, diabetes, atherosclerosis-related diseases, cardiovascular disease, hyperuricemia or a combination thereof.

### Claim 31 (depends on 24)

The method according to claim 24, wherein the composition comprises: (a) a safe and effective amount of Megamonas funiformis and/or its metabolites, and (b) a food acceptable or pharmaceutically acceptable carrier.

### Claim 32 (depends on 24)

The method according to claim 24, wherein the composition comprises 1×10−1 to 1×1020 cfu/mL or 1×10−1 to 1×1020 cfu/g of Megamonas funiformis, preferably 1×104 to 1×1015 cfu/mL or 1×104 to 1×1015 cfu/g of Megamonas funiformis, based on the total volume or total weight of the composition.

### Claim 33 (depends on 24)

The method according to claim 24, wherein the composition further comprises probiotics and/or prebiotics.

### Claim 34 (depends on 24)

The method according to claim 24, wherein the composition further comprises a substance capable of maintaining the vitality of Megamonas funiformis.

### Claim 35 (depends on 24)

The method according to claim 24, wherein the composition is selected from the group consisting of a food composition, a health care composition, a pharmaceutical composition, a beverage composition, a feed composition, or a combination thereof.

### Claim 36

(canceled)

### Claim 37 (depends on 24)

The method according to claim 24, wherein the Megamonas funiformis exhibits one or more activities from the group consisting of:
(i) reducing a blood glucose level in mammals;
(ii) ameliorating glucose intolerance in mammals;
(iii) ameliorating myocardial ischemia in mammals;
(iv) reducing a blood uric acid level in mammals;
(v) reducing a blood lipid level in mammals;
(vi) reducing body weight of mammals; and
(vii) ameliorating vasculopathy in mammals.

### Claim 38 (depends on 24)

The method according to claim 24, wherein the composition is in a unit dosage form, such as one tablet, one capsule or one vial, and the composition in each unit dosage form is of a mass of 0.05 g to 5 g, preferably 0.1 g to 1 g.

### Claim 39 (depends on 33)

The method according to claim 33, wherein the probiotics are selected from the group consisting of Lactic acid bacteria, Bifidobacteria, Lactobacillus acidophilus or a combination thereof,
the prebiotics are selected from the group consisting of fructooligosaccharide (FOS), galactooligosaccharide (GOS), xylooligosaccharide (XOS), lactosucrose (LACT), soybean oligosaccharides (SOS), Inulin, oligosaccharide or a combination thereof.

### Claim 40 (depends on 24)

The method according to claim 24, wherein the administration dosage is 0.01 to 5 g/50 kg body weight per day, preferably 0.1 to 2 g/50 kg body weight per day.
